Biogen Inc stock (US09062X1037): Goldman Sachs lifts target after strong Q1 and Leqembi momentum

Biogen’s Alzheimer’s drug Leqembi is gaining traction, Q1 2026 earnings beat expectations, and Goldman Sachs has just raised its price target on the stock. What is behind the renewed optimism – and which risks remain for investors?

Biogen Inc has moved back into the spotlight after a stronger-than-expected first quarter and growing momentum for its Alzheimer’s therapy Leqembi. Goldman Sachs recently increased its price target for Biogen shares from 238 USD to 250 USD while reiterating a buy rating, citing accelerating Leqembi uptake and promising data from a next?generation Alzheimer’s candidate, according to a report summarized by TheStreet on 05/16/2026 based on MarketScreener information (TheStreet as of 05/16/2026).

For Q1 2026, Biogen reported revenue of 2.48 billion USD, up about 2% year over year, and non?GAAP earnings per share of 3.57 USD, beating the consensus estimate of 2.95 USD. Leqembi generated 168 million USD in global in?market sales for the quarter, representing roughly 74% growth compared with the prior?year period, according to figures referenced in coverage of the company’s earnings call on 05/15/2026 (MarketBeat as of 05/16/2026).

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Biogen Inc
• Sector/industry: Biotechnology, neuroscience?focused pharmaceuticals
• Headquarters/country: Cambridge, Massachusetts, United States
• Core markets: Neurology and neurodegenerative diseases, primarily in the US, Europe and key Asian markets
• Key revenue drivers: Multiple sclerosis therapies, spinal muscular atrophy drug Spinraza, Alzheimer’s portfolio including Leqembi
• Home exchange/listing venue: Nasdaq Global Select Market (ticker: BIIB)
• Trading currency: US dollar (USD)

Biogen Inc: core business model

Biogen develops and commercializes therapies for serious neurological and neurodegenerative conditions. The company historically built its business around multiple sclerosis drugs but is now shifting its focus toward Alzheimer’s disease, other dementia?related indications and rare neurological disorders. The portfolio spans marketed products, late?stage clinical programs and earlier research collaborations.

Within this model, Biogen generates revenue mainly from branded prescription drugs that are frequently used in chronic conditions. This leads to recurring revenue streams but also exposes the company to patent expirations, generic competition and pricing pressures. Over the past several years, revenue from legacy multiple sclerosis treatments has come under pressure, intensifying the need for new growth drivers.

Leqembi, an anti?amyloid Alzheimer’s therapy co?developed with Eisai, is at the center of Biogen’s current strategy. The drug has full approval in the United States and is being rolled out across additional markets, with Medicare reimbursement in the US playing a crucial role in uptake. Biogen and Eisai share costs and profits, giving Biogen an important stake in the commercial success of the medicine.

Alongside Leqembi, Biogen also invests in next?generation Alzheimer’s assets that go beyond amyloid?beta and target tau or other mechanisms associated with disease progression. Recent clinical signals of tau reduction and cognitive benefit from a pipeline candidate have added to investor interest, as highlighted in the Goldman Sachs comment referenced by TheStreet on 05/16/2026 (TheStreet as of 05/16/2026).

Main revenue and product drivers for Biogen Inc

Biogen’s sales base is still anchored in neurology products beyond Alzheimer’s. Multiple sclerosis therapies like Tecfidera and Tysabri, as well as the rare disease drug Spinraza for spinal muscular atrophy, have long been key revenue contributors. However, competitive dynamics and patent cliffs have led to declining sales in some of these franchises, a trend that sector observers continue to monitor closely.

The Alzheimer’s franchise, centered on Leqembi, is increasingly viewed as the company’s main growth engine. With 168 million USD in global in?market Leqembi sales reported for Q1 2026 and growth of around 74% year over year, uptake appears to be accelerating from a relatively low base, according to company commentary summarized after the Q1 results on 05/15/2026 (MarketBeat as of 05/16/2026). Physician familiarity, diagnostic infrastructure and reimbursement pathways remain crucial factors for further expansion.

Biogen has launched primary care outreach initiatives intended to increase biomarker testing and earlier diagnosis among patients with cognitive complaints. According to TheStreet’s 05/16/2026 analysis of recent trends, early data from these programs suggest higher use of relevant biomarkers among participating physicians, which could support a broader eligible patient pool over time (TheStreet as of 05/16/2026). For investors, this operational push is relevant because it may directly influence the future revenue trajectory of Leqembi.

Beyond Alzheimer’s, Biogen’s pipeline includes candidates in areas such as depression, amyotrophic lateral sclerosis and other neuropsychiatric indications. While these projects are at different stages of development, they represent potential diversification away from a single?product dependency. At the same time, acquisitions, including the deal for Apellis mentioned in sector commentary, increase financial leverage and integration complexity, which can affect the company’s earnings profile in the medium term.

Industry trends and competitive position

The global Alzheimer’s treatment market is undergoing rapid change as disease?modifying therapies begin to reach patients. Biogen competes with alternative approaches from large pharmaceutical peers, including Eli Lilly’s Kisunla, which targets similar pathology. In this competitive setting, relative efficacy, safety, dosing convenience and real?world outcomes will likely determine how market share evolves over the coming years.

For now, Biogen and its partner Eisai hold a first?mover advantage in the fully approved US Alzheimer’s antibody segment, supported by established Medicare reimbursement structures. The Goldman Sachs analysis cited by TheStreet on 05/16/2026 points to Biogen’s perceived market leadership in this emerging category as one factor behind the higher 250 USD price target (TheStreet as of 05/16/2026). Nevertheless, evolving data from competitors could change the landscape.

Regulatory decisions remain important catalysts. Sector coverage has highlighted an upcoming US Food and Drug Administration decision on an Alzheimer’s?related asset known as IQLIK, expected on 08/24/2026. Commentary suggests that the outcome could be binary for sentiment around Biogen: a positive decision might support the stock, whereas a negative ruling or a complete response letter could weigh on expectations built into current valuations (TheStreet as of 05/16/2026). This underscores how closely the company’s fortunes are tied to regulatory and clinical news flow.

Why Biogen Inc matters for US investors

Biogen is directly relevant for US investors because its shares trade on the Nasdaq Global Select Market under the ticker BIIB, with liquidity and institutional ownership levels typical of a large?cap biotechnology stock. According to MarketBeat data as of the close on 05/15/2026, the stock ended the session at 192.95 USD, up about 0.83% on the day, and had risen roughly 9.6% since the start of the year (MarketBeat as of 05/16/2026).

Institutional investors play a significant role in the shareholder base. An example is Leuthold Group LLC, which disclosed purchases of Biogen shares in a recent regulatory filing highlighted by MarketBeat on 05/17/2026. In the same context, the outlet reiterated that Biogen’s Q1 2026 earnings per share of 3.57 USD exceeded the consensus forecast of 2.95 USD and that management has set full?year 2026 non?GAAP EPS guidance in the range of 14.25 to 15.25 USD (MarketBeat as of 05/17/2026). Analyst forecasts collected by the same source suggest expected EPS around 14.21 USD for the current year.

For US portfolio managers and retail investors alike, Biogen serves as a high?profile way to gain exposure to the emerging Alzheimer’s market and broader neuroscience innovation. At the same time, the stock reflects typical biotechnology risk factors, including binary regulatory events, trial outcomes and the need to balance investment in research with shareholder returns. The consensus rating compiled by MarketBeat and updated on 05/16/2026 shows a "Moderate Buy" stance based on a mix of buy and hold recommendations, underlining a spectrum of opinions among covering analysts (MarketBeat as of 05/16/2026).

Conclusion

Biogen is in the middle of a strategic transition from a reliance on multiple sclerosis drugs to a new growth phase driven by Alzheimer’s therapies and neuroscience innovation. The Q1 2026 earnings beat, strong Leqembi growth and raised Goldman Sachs price target to 250 USD underscore the optimism surrounding this shift, as reported by TheStreet on 05/16/2026 and MarketBeat on 05/17/2026 (TheStreet as of 05/16/2026, MarketBeat as of 05/17/2026). At the same time, declining legacy revenues, higher balance sheet leverage and dependence on key regulatory decisions create meaningful uncertainties that investors must weigh when assessing the stock’s risk?reward profile.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.